Objective To construct eukaryotic expression vector of hepatitis C virus (HCV) cytotoxic T-lymphocyte (CTL) epitopes, and to establish stable transfected CHO cell-lines.Methods The HCV CTL epitopes of different genotypes and the mouse H2 complex were predicted by bioinformatics, then synthesized and inserted into eukaryotic expression vector pEGFP-N3.The recombinant vector was transfected into CHO cells by lipofectamine 2000.After screening with G418, stably transfected CHO cell line was established.The expression of HCV multi-epitopes was identified by RT-PCR and western-blot and immunofluorescence.Results The eukaryotic expression vector was constructed successfully.The stable transfected CHO cell line was established.Conclusion The establishment of stable transfected CHO cell line and the expression of the target gene provide solid foundation for further experimental studies.
[1]Stoll-Keller F, Barth H, Fafi-Kremer S, et al.Developmentof hepatitis C virus vaccines:challenges and progress[J].Expert Rev Vaccines, 2009, 8 (3) :333-345.
|
[2]Yerly D, Heckerman D, Allen TM, et al.Increased cytotoxicT-lymphocyte epitope variant cross-recognition andfunctional avidity are associated with hepatitis C virusclearance[J].J Virol, 2008, 82 (6) :3147-3153.
|
[3]Takao Y, Yamada A, Yutani S, et al.Identification of newimmunogenic peptides in conserved regions of hepatitisC virus (HCV) 1b with the potentiality to generatecytotoxic T lymphocytes in HCV1b (+) HLA-A24 (+) patients[J].Hepatol Res, 2007, 37 (3) :186-195.
|
[4]Vider-Shalit T, Raffaeli S, Louzoun Y.Virus-epitopevaccine design:informatic matching the HLA-Ipolymorphism to the virus genome[J].Mol Immunol, 2007, 44 (6) :1253-1261.
|
[5]Shi L, Liu S, Fan GX, et al.Effective induction of type1 cytotoxic T cell responses in mice with DNA vaccineencoding two hepatitis C virus cytotoxic T lymphocyteepitopes[J].Viral Immunol, 2006, 19 (4) :702-711.
|
[6]Chang KM, Gruener NH, Southwood S, et al.Identification of HLA-A3 and-B7-restricted CTLresponse to hepatitis C virus in patients with acute andchronic hepatitis C[J].J Immunol, 1999, 162 (2) :1156-1164.
|
[7]Sallberg M, Zhang ZX, Chen M, et al.Immunogenicityand antigenicity of the ATPase/helicase domain of thehepatitis C virus non-structural 3 protein[J].J Gen Virol, 1996, 77 (Pt11) :2721-2728.
|
[8]Sarobe P, Lasarte JJ, García N, et al.Characterizationof T-cell responses against immunodominant epitopesfrom hepatitis C virus E2 and NS4a proteins[J].J ViralHepat, 2006, 13 (1) :47-55.
|
[9]李端, 谢玉梅, 薛小平, 等.中国丙型肝炎病毒细胞毒性T淋巴细胞表位预测及其多表位疫苗设计[J].中华肝脏病杂志, 2009, l7 (10) :786-787.
|
[10]Hurwitz JL, Zhan X, Brown SA, et al.HIV-1 vaccinedevelopment:tackling virus diversity with a multi-envelope cocktail[J].Front Biosci, 2008, 13:609-620.
|
[11]Yerly D, Heckerman D, Allen T, et al.Design, expression, and processing of epitomized hepatitis C virus-encodedCTL epitopes[J].J Immunol, 2008, 181 (9) :6361-6370.
|
[12]Koh S, Bertoletti A.Viral hepatitis and serotonin:alteringcytotoxic T-lymphocyte function in the liver[J].ExpertRev Vaccines, 2009, 8 (1) :29-32.
|
[13]Encke J, Radunz W, Eisenbach C, et al.Development of aheterologous, multigenotype vaccine against hepatitis Cvirus infection[J].Eur J Clin Invest, 2007, 37 (5) :396-406.
|
[14]Azizi A, Diaz-Mitoma F.Viral peptide immunogens:current challenges and opportunities[J].J Pept Sci, 2007, 13 (12) :776-786.
|